Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 931 to 940 of 1911 total matches.
A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
:e2128652.
Both vaccines were given on days 0, 28, and 168.3,4
In the PROTECT trial, 1607 adults were ...
The FDA has licensed PreHevbrio (VBI Vaccines), a
recombinant, 3-antigen, 3-dose hepatitis B vaccine,
for the prevention of infection caused by all known
subtypes of hepatitis B virus (HBV) in adults. It has
been available in Israel since 2000.
IV Meloxicam Returns for Treatment of Pain
The Medical Letter on Drugs and Therapeutics • Sep 29, 2025 (Issue 1738)
: Generally well tolerated in clinical trials.
▶ Dosage: 30 mg once/day by IV bolus over 15 seconds.
▶ Cost ...
The FDA has approved Xifyrm (Azurity) and
Qamzova (Nanjing Delova), two new intravenous (IV)
formulations of the nonsteroidal anti-inflammatory
drug (NSAID) meloxicam, for use alone or in
combination with non-NSAID analgesics for treatment
of moderate to severe pain in adults. Anjeso, the first
IV formulation of meloxicam, was discontinued in
2022 for commercial reasons.
Med Lett Drugs Ther. 2025 Sep 29;67(1738):158-60 doi:10.58347/tml.2025.1738b | Show Introduction Hide Introduction
Nimodipine for Cerebral Vasospasm Subarachnoid Hemorrhage
The Medical Letter on Drugs and Therapeutics • May 19, 1989 (Issue 792)
for 21 days, decreased the incidence of severe
neurological damage. Persistent, severe deficits or death ...
Cerebral arterial spasm frequently causes ischemic neurological damage after subarachnoid hemorrhage from a ruptured intracranial aneurysm. Nimodipine (Nimotop - Miles), a 1,4-dihydropyridine calcium-entry blocker, was recently approved by the US Food and Drug Administration (FDA) for oral treatment of such patients; an intravenous preparation is available only for investigational use.
Prevention And Treatment of Cholera
The Medical Letter on Drugs and Therapeutics • Nov 15, 1991 (Issue 857)
that lasts from three to five days; severely affected patients may lose more than one liter of fluid per hour ...
Almost 300,000 cases of epidemic cholera have occurred in the Western Hemisphere in 1991, mostly in South and Central America (Morbid Mortal Weekly Rep, 40:562, Aug 16, 1991). The few US cases caused by the epidemic strain have been in returning travelers or associated with contaminated food they brought back illicitly, with no secondary spread to date.
Sotalol for Cardiac Arrhythmias
The Medical Letter on Drugs and Therapeutics • Apr 02, 1993 (Issue 893)
b.i.d., which can be
increased to 240 mg or 320 mg per day, divided b.i.d. or t.i.d.; two to three days ...
Sotalol (hydrochloride (Betapace -Berlex; Sotacor -Bristol Laboratories of Canada), an antiarrhythmic drug that prolongs repolarization (Class III) and also has beta-adrenergic-blocking activity (Class II), was recently approved by the US Food and Drug Administration (FDA) for oral treatment of life-threatening ventricular arrhythmias.
Zolpidem For Insomnia
The Medical Letter on Drugs and Therapeutics • Apr 30, 1993 (Issue 895)
of zolpidem are dose-related. With doses of up to
10 mg, dizziness, headache, nausea, diarrhea, and next-day ...
Zolpidem (Ambien - Searle), an imidazopyridine hypnotic available in Europe for several years, was recently approved by the US Food and Drug Administration for short-term treatment of insomnia.
Extended-Release Isosorbide Mononitrate for Angina
The Medical Letter on Drugs and Therapeutics • Feb 04, 1994 (Issue 915)
treatment of chronic stable angina
** Cost to the pharmacist for a 30-day supply according to Average ...
Isosorbide mononitrate, the major active metabolite of isosorbide dinitrate, was first approved in the USA for oral use in patients with chronic stable angina in 1992 (Medical Letter, 34:61, 1992). Now an extended-release formulation of isosorbide mononitrate (Imdur -Key) has been approved by the US Food and Drug Administration.
Fluvastatin for Lowering Cholesterol
The Medical Letter on Drugs and Therapeutics • May 27, 1994 (Issue 923)
54.02
maximum: 40 mg once 152.71
* For 30 days’ treatment according to Average Wholesale Price ...
Fluvastatin (Lescol - Sandoz), an HMG-CoA reductase inhibitor, was recently marketed in the USA for treatment of hypercholesterolemia. A synthetic mevalonolactone derivative, it is chemically distinct from previously available drugs in this class.
Sildenafil: An Oral Drug for Impotence
The Medical Letter on Drugs and Therapeutics • May 08, 1998 (Issue 1026)
after
taking 25 mg of sildenafil or placebo once daily for 7 days; the number of erections within 2 ...
Sildenafil citrate (Viagra - Pfizer) is the first oral drug approved by the FDA for treatment of erectile dysfunction. Alprostadil is also marketed for this indication but must be injected into the corpus cavemosum (Caverject) or pushed into the urethra (MUSE).
Modafinil for Narcolepsy
The Medical Letter on Drugs and Therapeutics • Mar 26, 1999 (Issue 1049)
). With 600 mg/day, one patient developed symptoms of
psychosis. Dependence on modafinil or withdrawal ...
Modafinil (Provigil), a benzhydryl sulfinylacetamide non-amphetamine stimulant that has been used in Europe since 1995, has now been approved by the FDA for treatment of excessive daytime sleepiness associated with narcolepsy.
